Expression of A disintegrin and metalloprotease 8 is associated with cell growth and poor survival in colorectal cancer

[1]  Lei Wang,et al.  Expression of A disintegrin and metalloprotease 8 is associated with cell growth and poor survival in colorectal cancer , 2014, BMC Cancer.

[2]  M. Duffy,et al.  ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasis , 2013, EMBO molecular medicine.

[3]  Wei Li,et al.  Protein predictive signatures for lymph node metastasis of gastric cancer , 2013, International journal of cancer.

[4]  Xiaojian Wu,et al.  Tumor-Infiltrating Mast Cells in Colorectal Cancer as a Poor Prognostic Factor , 2013, International journal of surgical pathology.

[5]  Jianxing He,et al.  Protective effects of ADAM8 against cisplatin‐mediated apoptosis in non‐small‐cell lung cancer , 2013, Cell biology international.

[6]  T. Yokota.  Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers? , 2012, Anti-cancer agents in medicinal chemistry.

[7]  Yun Zhang,et al.  High ADAM8 Expression is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma , 2012, Pathology & Oncology Research.

[8]  Y. Tu,et al.  Overexpression of a disintegrin and metalloprotease 8 in human gliomas is implicated in tumor progression and prognosis , 2012, Medical Oncology.

[9]  R. Seemann,et al.  ADAM8 in squamous cell carcinoma of the head and neck: a retrospective study , 2012, BMC Cancer.

[10]  Mingmei Liao,et al.  Upregulation of a Disintegrin and Metalloprotease 8 Influences Tumor Metastasis and Prognosis in Patients with Osteosarcoma , 2012, Pathology & Oncology Research.

[11]  R. Kelley,et al.  Biomarker use in colorectal cancer therapy. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

[12]  P. Johnston,et al.  Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17. , 2011, Cancer research.

[13]  L. Terracciano,et al.  Clinicopathological and protein characterization of BRAF‐ and K‐RAS‐mutated colorectal cancer and implications for prognosis , 2010, International journal of cancer.

[14]  F. Lecanda,et al.  Novel alternatively spliced ADAM8 isoforms contribute to the aggressive bone metastatic phenotype of lung cancer , 2010, Oncogene.

[15]  G. Weskamp,et al.  ADAM8 is a negative regulator of retinal neovascularization and of the growth of heterotopically injected tumor cells in mice , 2010, Journal of Molecular Medicine.

[16]  A. Schäffer,et al.  Distinct Genetic Alterations in Colorectal Cancer , 2010, PloS one.

[17]  J. Ku,et al.  Promoter hypermethylation of the ADAM23 gene in colorectal cancer cell lines and cancer tissues , 2009, International journal of cancer.

[18]  D. Postma,et al.  Expression of ADAMs (“a disintegrin and metalloprotease”) in the human lung , 2009, Virchows Archiv.

[19]  Valkovskaya Nv.  Hypoxia-dependent expression of ADAM8 in human pancreatic cancer cell lines. , 2008 .

[20]  N. Valkovskaya.  Hypoxia-dependent expression of ADAM8 in human pancreatic cancer cell lines. , 2008, Experimental oncology.

[21]  D. Notterman,et al.  Expression of L1-CAM and ADAM10 in human colon cancer cells induces metastasis. , 2007, Cancer research.

[22]  H. Friess,et al.  ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer , 2007, Journal of cellular and molecular medicine.

[23]  H. Hartung,et al.  The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies , 2007, Neurobiology of Disease.

[24]  G. Kristiansen,et al.  ADAM8 expression in prostate cancer is associated with parameters of unfavorable prognosis , 2006, Virchows Archiv.

[25]  D. Wildeboer,et al.  Metalloproteinase Disintegrins ADAM8 and ADAM19 Are Highly Regulated in Human Primary Brain Tumors and their Expression Levels and Activities Are Associated with Invasiveness , 2006, Journal of neuropathology and experimental neurology.

[26]  Y. Doki,et al.  Overexpression of ADAM9 enhances growth factor-mediated recycling of E-cadherin in human colon cancer cell line HT29 cells. , 2005, Experimental cell research.

[27]  C. Da Cunha,et al.  A simple and fast densitometric method for the analysis of tyrosine hydroxylase immunoreactivity in the substantia nigra pars compacta and in the ventral tegmental area. , 2005, Brain research. Brain research protocols.

[28]  R. Houlston,et al.  Systematic review of microsatellite instability and colorectal cancer prognosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Yusuke Nakamura,et al.  ADAM8 as a Novel Serological and Histochemical Marker for Lung Cancer , 2004, Clinical Cancer Research.

[30]  S. Loening,et al.  The membrane proteases adams and hepsin are differentially expressed in renal cell carcinoma. Are they potential tumor markers? , 2004, The Journal of urology.

[31]  Z. Wenhua,et al.  Multivariate regression analysis of prognostic factors in colorectal cancer , 2003 .

[32]  Leila Mohammadi,et al.  BMC Cancer , 2001 .

[33]  D. Barnes,et al.  Multiple tissue core arrays in histopathology research: a validation study , 2000, The Journal of pathology.

[34]  H. Jockusch,et al.  Tumor Necrosis Factor α Induces a Metalloprotease-Disintegrin, ADAM8 (CD 156): Implications for Neuron–Glia Interactions during Neurodegeneration , 2000, The Journal of Neuroscience.